Search

  • Search

    Toxicity study in naïve mice

    BiconY Therapeutics GmbH

    Toxicity study in naïve mice

    1. Competition notice published

      Oct 7, 2:58 PMOctober 7, 2025 2:58 PM

    2. Supplier selection

      Nov 27, 12:00 AMNovember 27, 2025 12:00 AM

    3. Contract signed

      Nov 28, 12:00 AMNovember 28, 2025 12:00 AM

    4. Contract start date

      Dec 1, 12:00 AMDecember 1, 2025 12:00 AM

    5. Result notice published

      Dec 15, 7:17 AMDecember 15, 2025 7:17 AM

    6. Contract end date

      May 29, 12:00 AMMay 29, 2026 12:00 AM

    Brief

    Germany: Tenders/BiconY Therapeutics GmbH/Toxicity study in naïve mice

    Awarded

    The competition has ended and a winner has been selected.

    Brief

    The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies

    Result

    Winner
    vivo Science GmbH
    Number of bids
    3
    Contract value
    -€1

    About the bid

      The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies

      Contact phone
      +49 69 7191890-12
      Contact email
      bicony.tenderprocedure@fgvw.de
      Address
      Lagerhofstraße 4, 04103 Leipzig

    Custom Assessment Criteria

    Start a free trial to ask your own questions about the tender and get AI-generated answers.

    Award Criteria

    • Description

      The award criterion price will be evaluated as follows: The lowest bid price according to the Price sheet (Form for offer) will be awarded the highest number of points (5). The number of points for the prices offered will be determined as follows: Points of the bidder = lowest price x 5 / bidder's offered price The score achieved is rounded to two decimal places.

      Evaluation Method

      The lowest bid price according to the Price sheet (Form for offer) will be awarded the highest number of points (5). The score achieved is rounded to two decimal places.

    • Description

      The award criterion Date of final QA Report (audited) will be evaluated as follows: Date Points Till March 27, 2026 5 Till April 3, 2026 4 Till April 11, 2026 3 Till April 18, 2026 2 Till April 25, 2026 1 Till May 29, 2026 0 Please note: 29 May 2026 is the latest possible date A total of up to 10 points can be achieved (5 price points and 5 timeline points for final QA report audited).

      Evaluation Method

      The evaluation is based on the date of the final QA Report (audited) as follows:

      • Till March 27, 2026: 5 points
      • Till April 3, 2026: 4 points
      • Till April 11, 2026: 3 points
      • Till April 18, 2026: 2 points
      • Till April 25, 2026: 1 point
      • Till May 29, 2026: 0 points

      29 May 2026 is the latest possible date. A total of up to 10 points can be achieved (5 price points and 5 timeline points for final QA report audited).

    Qualification requirements

      Found no qualification requirements in the contract notice.

    Previous Contract Winners

    Start a free trial to see who has won similar tenders for this buyer.

    See the full notice

    Contracting authority
    BiconY Therapeutics GmbH
    Title
    Toxicity study in naïve mice
    Type
    ResultPrequalification
    Main code
    73000000Research and development services and related consultancy services
    Supplemental codes

    No supplemental codes from buyer…

    Active similar competitions

    • Charité - Universitätsmedizin Berlin

      Forsknings- og analyselaboratorier

      Rahmenvertrag über In-Vivo-Studien an NB-PDX-Modellen in Mäusen

      Die Charité - Universitätsmedizin Berlin benötigt einen Rahmenvertrag für In-Vivo-Studien an patientenabgeleiteten Neuroblastom-Xenograft-Modellen (NB-PDX-Modellen) in Mäusen über 4 Jahre. Die Dienstleistungen umfassen Therapie-, Charakterisierungs- oder Bioverteilungs-/Pharmakokinetikstudien sowie die Entnahme von PDX-Tumormaterial und sollen in Berlin erbracht werden. Die Vergabe erfolgt auf Basis des niedrigsten Preises (100%). Für die Qualifikation sind zwei Unternehmensreferenzen aus den letzten 6 Jahren (2020-2025) über vergleichbare In-Vivo-Studien in Mäusen erforderlich, die sowohl Therapiestudien als auch Charakterisierungsstudien mit Neuroblastom-PDX-Modellen und die Entnahme von PDX-Tumormaterial umfassen müssen. Zudem ist eine gültige AAALAC-Zertifizierung (Association for Assessment and Accreditation of Laboratory Animal Care International) nachzuweisen.

      Framework agreementSep 22, 2026
      Oct 23, 2026(10 days)

    • BiconY Therapeutics GmbH

      Helse- og sosial tjenesteyting

      Central Laboratory Services for Clinical Trial

      BiconY Therapeutics GmbH needs central laboratory services for two phase I/IIa clinical trials over 18 months. The services include collection logistics, processing, analysis, management, distribution, and long-term storage of biological specimens, specifically cytokine analysis in serum and isolation of peripheral blood mononuclear cells (PBMC). The central laboratory must be accredited according to ISO 15189 (or equivalent, e.g., CAP/CLIA) and operate in compliance with GCP/GCLP. Suppliers must provide at least five references as a central laboratory in clinical studies with cytokine multiplex analysis and/or specimen management since October 1, 2022, and submit a self-declaration on compliance with Good Clinical Practice (ICH E6) and GDPR.

      CompetitionOct 3, 2026
      Nov 4, 2026(22 days)